Skip to main content
. Author manuscript; available in PMC: 2022 Feb 14.
Published in final edited form as: J Cardiothorac Vasc Anesth. 2021 Apr 25;35(9):2651–2658. doi: 10.1053/j.jvca.2021.04.030

Fig 2.

Fig 2.

No association between FEIBA dosage and composite thrombotic events. (A) Intraop dose = units of FEIBA given intraoperatively, ICU dose = units of FEIBA given between postoperative day zero-two, total dose = total dose of FEIBA from intraoperative period to POD two. (B) No event, total units of FEIBA given to patients with no thrombotic events in 30 days postoperatively; thrombotic event, total units of FEIBA given to patients with postoperative composite thrombotic events within 30 days. No significant difference by two-sided t test. (C) Receiver operator curve (ROC) for composite thrombotic event per unit of FEIBA administered (AUC: 0.532, p = 0.755). AUC, area under the curve; FEIBA, Factor Eight Inhibitor Bypassing Activity; ICU, intensive care unit.